摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-7-[(2R,5S)-5-(羟甲基)-2,5-二氢呋喃-2-基]-7H-吡咯并[2,3-d]嘧啶-5-甲腈 | 115044-83-2

中文名称
4-氨基-7-[(2R,5S)-5-(羟甲基)-2,5-二氢呋喃-2-基]-7H-吡咯并[2,3-d]嘧啶-5-甲腈
中文别名
——
英文名称
4-Amino-5-cyano-7-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)pyrrolo<2,3-d>pyrimidine
英文别名
2',3'-dideoxy-2',3'-didehydrotoyocamycin;7H-Pyrrolo(2,3-d)pyrimidine-5-carbonitrile, 4-amino-7-(2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-, (2R-cis)-;4-amino-7-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile
4-氨基-7-[(2R,5S)-5-(羟甲基)-2,5-二氢呋喃-2-基]-7H-吡咯并[2,3-d]嘧啶-5-甲腈化学式
CAS
115044-83-2
化学式
C12H11N5O2
mdl
——
分子量
257.252
InChiKey
MKPNXBOGNDTEQA-DTWKUNHWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    110
  • 氢给体数:
    2
  • 氢受体数:
    6

SDS

SDS:934df7efee9c68950a6a456b9b1a7b2d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-氨基-7-[(2R,5S)-5-(羟甲基)-2,5-二氢呋喃-2-基]-7H-吡咯并[2,3-d]嘧啶-5-甲腈 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 19.0~22.0 ℃ 、68.94 kPa 条件下, 反应 5.0h, 以89%的产率得到4-Amino-5-cyano-7-(2,3-dideoxy-β-D-glycero-pentofuranosyl)pyrrolo<2,3-d>pyrimidine
    参考文献:
    名称:
    Nucleic Acid-Related Compounds. 88. Efficient Conversions of Ribonucleosides into Their 2',3'-Anhydro, 2'(and 3')-Deoxy, 2',3'-Didehydro-2',3'-dideoxy, and 2',3'-Dideoxynucleoside Analogs
    摘要:
    Treatment of purine, pyrimidine, and modified purine (antibiotic) ribonucleosides with 2-acetoxy-2-methylpropanoyl (alpha-acetoxyisobutyryl) bromide in acetonitrile gave mixtures of 2',3'-bromohydrin acetates with different O5' substituents. Significant amounts of 5'-unprotected (hydroxyl) bromo acetates were obtained in some cases, and formation of 2',3'-O-isopropylidene derivatives as minor byproducts was detected for the first time. Acid-catalyzed nucleophilic displacement of chloride by bromide occurred with 2-amino-6-chloropurine riboside, but no substitution of fluoride by bromide was detected with 6-amino-2-fluoropurine riboside. Treatment of the trans bromo acetate mixtures obtained from purine-type nucleosides with Dowex 1 x 2 (OH-) in methanol gave the 2',3'-anhydro (ribo epoxide) compounds. Radical-mediated hydrogenolytic debromination and deprotection gave 2'- and 3'-deoxynucleosides. Treatment of the bromo acetate mixtures with zinc-copper couple or acetic acid-activated zinc effected reductive elimination, and deprotection gave 2',3'-didehydro-2',3'-dideoxy compounds which were hydrogenated to give 2',3'-dideoxynucleosides. A number of these analogues have potent inhibitory activity against AIDS and hepatitis B viruses. New C-13 NMR data for several types of unsaturated-sugar nucleosides are tabulated. These procedures are directly applicable for the preparation of L-didehydro-dideoxy and L-dideoxy nucleoside analogues.
    DOI:
    10.1021/jo00129a034
  • 作为产物:
    参考文献:
    名称:
    Nucleic Acid-Related Compounds. 88. Efficient Conversions of Ribonucleosides into Their 2',3'-Anhydro, 2'(and 3')-Deoxy, 2',3'-Didehydro-2',3'-dideoxy, and 2',3'-Dideoxynucleoside Analogs
    摘要:
    Treatment of purine, pyrimidine, and modified purine (antibiotic) ribonucleosides with 2-acetoxy-2-methylpropanoyl (alpha-acetoxyisobutyryl) bromide in acetonitrile gave mixtures of 2',3'-bromohydrin acetates with different O5' substituents. Significant amounts of 5'-unprotected (hydroxyl) bromo acetates were obtained in some cases, and formation of 2',3'-O-isopropylidene derivatives as minor byproducts was detected for the first time. Acid-catalyzed nucleophilic displacement of chloride by bromide occurred with 2-amino-6-chloropurine riboside, but no substitution of fluoride by bromide was detected with 6-amino-2-fluoropurine riboside. Treatment of the trans bromo acetate mixtures obtained from purine-type nucleosides with Dowex 1 x 2 (OH-) in methanol gave the 2',3'-anhydro (ribo epoxide) compounds. Radical-mediated hydrogenolytic debromination and deprotection gave 2'- and 3'-deoxynucleosides. Treatment of the bromo acetate mixtures with zinc-copper couple or acetic acid-activated zinc effected reductive elimination, and deprotection gave 2',3'-didehydro-2',3'-dideoxy compounds which were hydrogenated to give 2',3'-dideoxynucleosides. A number of these analogues have potent inhibitory activity against AIDS and hepatitis B viruses. New C-13 NMR data for several types of unsaturated-sugar nucleosides are tabulated. These procedures are directly applicable for the preparation of L-didehydro-dideoxy and L-dideoxy nucleoside analogues.
    DOI:
    10.1021/jo00129a034
点击查看最新优质反应信息

文献信息

  • Synthesis and Evaluation of Certain Thiosangivamycin Analogs as Potential Inhibitors of Cell Proliferation and Human Cytomegalovirus
    作者:Steven H. Krawczyk、Thomas E. Renau、M. Reza Nassiri、Allison C. Westerman、Linda L. Wotring、John C. Drach、Leroy B. Townsend
    DOI:10.1021/jm00020a027
    日期:1995.9
    7-substituted 4-aminopyrrolo[2,3-d]pyrimidines related to the nucleosides toyocamycin and thiosangivamycin were prepared and tested for their activity against human cytomegalovirus (HCMV). The nucleosides 2'-deoxytoyocamycin (1), xylo-toyocamycin (2), 3'-deoxytoyocamycin (3), 2',3'-dideoxy-2',3'-didehydrotoyocamycin (4), 2',3'-dideoxytoyocamycin (5), ara-toyocamycin (6), 2'-deoxy-2'-amino-ara-toyocamycin
    制备了一系列与核苷丰卡霉素和硫代桑奇霉素有关的7-取代的4-氨基吡咯并[2,3-d]嘧啶,并测试了它们对人巨细胞病毒(HCMV)的活性。核苷2'-脱氧代代霉素(1),木糖-代代霉素(2),3'-脱氧代代霉素(3),2',3'-脱氧代代-2',3'-脱氢代代代霉素(4),2',3'-用就地生成的硫化氢处理二脱氧代代霉素(5),阿拉伯代代霉素(6),2'-脱氧-2'-氨基-代代代霉素(7)和5'-脱氧代代霉素(8)。 thiosangivamycin类似物(9-16)。通过修改文献方法合成氰基衍生物1-8。所有的硫代酰胺衍生物(9-16)均具有抗HCMV的活性,IC50为0.5至6 microM。大多数还对1型单纯疱疹病毒(HSV-1)具有活性,但浓度较高。在两种人类细胞系中,抗病毒活性并未与细胞毒性完全分开。糖基上修饰的位置强烈影响抗增殖活性。与在2',5'或2',3'位置进行修饰的木糖基和
  • Pyrrolo[2,3-d]pyrimidine nucleoside analogs
    申请人:——
    公开号:US20020035077A1
    公开(公告)日:2002-03-21
    Compositions and methods for pyrrolo[2,3-d]pyrimidine nucleoside analogs having substituents at the C4′ and C5′ positions of the ribofuranose moiety are presented. Contemplated compositions exhibit, among other things, anti-cancer and immunomodulating effects at reduced cytotoxicity.
    本发明提供了在核糖苷骨架的C4'和C5'位置具有取代基的吡咯[2,3-d]嘧啶核苷类似物的组合物和方法。考虑到的组合物在减少细胞毒性的情况下表现出抗癌和免疫调节等效果。
  • KRAWCZYK, STEVEN H.;TOWNSEND, LEROY B., NUCLEOSIDES AND NUCLEOTIDES, 8,(1989) N, C. 97-115
    作者:KRAWCZYK, STEVEN H.、TOWNSEND, LEROY B.
    DOI:——
    日期:——
  • PYRROLO(2,3-D)PYRIMIDINE NUCLEOSIDE ANALOGS
    申请人:Ribapharm, Inc.
    公开号:EP1363581A2
    公开(公告)日:2003-11-26
  • US6831069B2
    申请人:——
    公开号:US6831069B2
    公开(公告)日:2004-12-14
查看更多

同类化合物

(2R,3S,5R)-5-(4-氨基-7H-吡咯[2,3-D]嘧啶-7-基-2 -(羟甲基)四氢呋喃-3-醇 鲁索替尼 鲁索利尼杂质C 迪高替尼 诺那吡胺 螺[4.4]壬烷-1-酮,6-氨基-,(5S,6S)- 苯酚,2,4-二氯-5-肼-,单盐酸 苯并呋喃,2,3-二氢-3-(1-甲基乙基)- 聚(氧代-1,2-乙二基),a-甲基-w-[[3,4,4,4-四氟-2-[1,2,2,2-四氟-1-(三氟甲基)乙基]-1,3-二(三氟甲基)-1-丁烯-1-基]氧代]- 维贝格龙 磷酸鲁索替尼 甲基7-(2-甲氧基乙基)-1,3-二甲基-2,4-二羰基-2,3,4,7-四氢-1H-吡咯并[2,3-D]嘧啶-6-羧酸酯 托法替尼杂质28 托法替尼杂质2 托伐替尼杂质T 异丙基2-氨基-4-甲氧基-7h-吡咯并[2,3-d]嘧啶-6-羧酸 巴里替尼杂质5 巴瑞替尼 巴瑞克替尼杂质 巴瑞克替尼中间体3 巴瑞克替尼中间体1 外消旋鲁替替尼-d8 培美酸 吡啶,1-[(2,5-二甲基苯基)甲基]-1,2,3,6-四氢- 吡咯并[1,2-a]嘧啶-3-羧酸 吡咯并[1,2-F]嘧啶-3-甲酸乙酯 吡咯并[1,2-A]嘧啶-6-羧酸 吡咯并[1,2-A]嘧啶-6-甲醛 叔丁基2-氨基-4-氯-5H-吡咯并[3,4-D]嘧啶-6(7H)-羧酸酯 叔丁基-4-氯-2-吗啉代-7H-吡咯并[2,3-D]嘧啶-7-甲酸甲酯 十二烷-1,12-二基二(苯甲基二甲基铵)二氯化 亚乙基,2-氨基-1-(乙酯基<乙氧羰基>)-2-(甲酰基亚氨基)-,(2Z)-(9CI) 二环[2.2.1]庚-5-烯-2-羧酸,丁基酯,(1R,2R,4R)- [4-(1H-吡唑-4-基)-7H-吡咯并[2,3-D]嘧啶-7-基]甲基特戊酸酯 [3-(4-氨基-7H-吡咯并[2,3-d]嘧啶-7-基)环戊基]甲醇 [1-(乙基磺酰基)-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]氮杂环丁烷-3-基]乙腈磷酸盐 S-鲁索替尼 PF-04965842(阿布罗替尼) N-苯基-5H-吡咯并(3,2-d)嘧啶-4-胺 N-苄基-7H-吡咯并[2,3-d]嘧啶-4-胺 N-苄基-5H-吡咯并[3,2-d]嘧啶-4-胺 N-甲基-N-((3S,4S)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺 N-甲基-N-((3R,4R)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺 N-甲基-7h-吡咯并[2,3-d]嘧啶-4-胺 N-甲基-1-((1R,4R)-4-(甲基(7H吡咯[2,3-D]嘧啶-4-基)氨基)环己基)甲磺酰胺富马酸甲酯 N-(5-溴-4-氯-7H-吡咯并[2,3-d]嘧啶-2-基)-2,2-二甲基-丙酰胺 N-(4-甲氧基苯基)-5H-吡咯并(3,2-d)嘧啶-4-胺 N-(4-氯-7H-吡咯并[2,3-D]嘧啶-2-基)-2,2-二甲基丙酰胺 N-(4-氯-5-碘-7H-吡咯[2,3-D]嘧啶-2-基)-2,2-二甲基丙酰胺 N-(4-氯-5-氰基-7H-吡咯并[2,3-d]嘧啶-2-基)-2,2-二甲基丙酰胺